Tacrolimus is a drug used to help reduce the risk of rejection by the body of organ and bone marrow transplants.
Researchers have developed a ground-breaking procedure that could avoid the need for transplant patients to spend the rest of their lives taking a cocktail of drugs to stop their system from rejecting their new organ, according to a series of papers in the August issue of Transplant International.
A new study documents malformations seen in an infant born to a kidney transplant recipient who had taken mycophenolate mofetil (MMF), a widely used immunosuppressant available commercially as Cellcept.
Treating relapsed follicular lymphoma patients with a milder chemotherapy regimen before they receive a blood stem cell transplant from a donor resulted in long-term complete remission for 45 of 47 patients in a clinical trial, researchers at The University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.
Garcia, et al reported their experience with renal transplantation in 38 children (40 transplant), ages 1-5 years over a 16 year period.
A group of German scientists has synthesized a new compound that dramatically decreases the damage to neurons in rats demonstrating stroke symptoms.
Psoriasis, a chronic skin condition characterized by thick, red, scaly patches that itch and bleed, not only makes the activities of daily life difficult, but also can affect a person's emotional well being.
The American Academy of Dermatology (Academy) has issued a statement in response to the U.S. Food and Drug Administration’s (FDA) announcement that a black box warning will be added to the labeling and a medication guide will be distributed for the topical calcineurin inhibitors (TCIs), pimecrolimus and tacrolimus.
Liver transplant patients with hepatitis C virus (HCV) achieved significantly better long-term viral response when taking the immunosuppressive agent Cyclosporine along with interferon-ribavirin combination therapy. Cyclosporine also showed efficacy against Hepatitis C virus in vitro.
A new study led by researchers at the UCLA Heart Transplant Program showed that one particular combination using tacrolimus (TAC or PrografÒ also known as FK506) had significant anti-rejection benefits for heart transplant patients over other combinations.
Protopic and Elidel, two treatments for eczema approved in 2000 and 2001, have now been found to cause cancer in three different animal species.
A number of clinical symptoms and signs are included under the broad group Rosacea. Facial flushing, the appearance of broken blood vessels and persistent redness of the face, eruption of inflamed spots & pimples, on the face and thickening of the sebaceous glands of the nose, with swelling & congestion in that area.
Transplant researchers at the University of Pittsburgh's Thomas E. Starzl Transplantation Institute have dramatically improved intestinal transplant graft survival, and reduced rejection and infection rates by successfully using a novel immunosuppression minimization protocol, thus improving patients' overall quality of life and avoiding the use of several anti-rejection drugs, which can cause serious infections and major complications.
Patients who suffer a loss of cognitive and motor function as a result of stem cell transplantation for severe blood disorders are likely to see those functions return to previous levels after one year, according to a new study in the November 15, 2004, issue of Blood, the official journal of the American Society of Hematology.
“The big advantage [of this combination of drugs] is that the incidence of rejection is significantly decreased,” he says. “These results could change the standard of care for liver transplant recipients.”
Patients with vitiligo, a skin disorder characterized by patches of white, or de-pigmented skin, had better repigmentation of these patches when they were treated with a combination of laser therapy and tacrolimus ointment than patients treated with laser therapy alone
A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.
A drug duo appears to be a safe and effective way to prevent a serious condition called graft-versus-host-disease (GVHD) in youngsters undergoing a stem cell transplant